Clinical Trial Update: Comparison Study of Vasovist® Magnetic Resonance Angiography (MRA) and an MRA With a Conventional Extracellular Contrast Agent With X-ray Angiography in Patients With Peripheral Artery Disease [Phase 3]

View source ↗

Summary

Phase 3 trial comparing Vasovist (gadofosveset trisodium) for MR angiography to a conventional iodinated extracellular contrast agent with X-ray angiography in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral Artery Disease

Drugs mentioned

• Iodinated contrast agent (conventional extracellular)
• Vasovist (gadofosveset trisodium)

Snippet

Sponsor: Bayer | Conditions: Peripheral Vascular Diseases | Phase 3 | Status: COMPLETED